PRIMED Risk

• Research type

  Research Study

• Full title

  Prospective Investigation of Markers for Elevated Delirium (PRIMED) Risk

• IRAS ID

  234979

• Contact name

  Daniel Davis

• Contact email

  daniel.davis@ucl.ac.uk

• Sponsor organisation

  UCL

• Clinicaltrials.gov Identifier

  Z6364106 2018 11 11, Data Protection; B1262 FI0153318, UCL Insurance

• Duration of Study in the UK

  2 years, 11 months, 28 days

• Research summary

  Background
  Delirium is a syndrome of severe brain dysfunction caused by acute illness. It affects at least 1 in 8 hospitalised patients. Several studies show that delirium is linked with both high risk of new dementia, and worsening of existing dementia. This is extremely important because it suggests that targeting delirium may be a beneficial intervention in dementia prevention.

  Yet our understanding of the delirium-dementia relationship remains poor. A major gap is that we have little systematic understanding of the underlying pathophysiology in delirium, and the extent to which it is shared or distinct from dementia.

  Main Hypotheses
  1. Biomarkers of acute CNS injury and/or clinical delirium are associated with faster cognitive decline, regardless of acuity of insult (e.g. medical, surgical, anaesthetic)
  2. Biomarkers of acute CNS injury and chronic neurodegeneration interact multiplicatively, being associated with fastest degree of cognitive decline

  Aims
  This project aims to understand mechanisms underlying delirium and adverse outcomes by establishing a platform for biomarker research (e.g. blood, CSF, cerebral monitoring, digital wearables). There will be overlap through co-recruitment into an existing population-based sample – Delirium and Population Health Informatics (DELPHIC) Study which tracks cognitive function before, during and after hospitalisation in delirium cases and controls.

  PRIMED Risk will offer comprehensive capture of delirium biomarkers in multiple settings (medical, surgical, critical care, community patients) which will be informative for a range of future studies.

• REC name

  London - South East Research Ethics Committee

• REC reference

  18/LO/2073

• Date of REC Opinion

  14 Mar 2019

• REC opinion

  Further Information Favourable Opinion